Free Trial Information
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...spots, with the billionaire family offices of Dietmar Hopp...
Read More
BioCentury | Aug 15, 2020
Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

...then diversified its investor base as it prepared to go public. Billionaire entrepreneur and investor Dietmar Hopp...
Read More
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...proposed range of $14-$16, it would raise $200 million and be valued at $2.6 billion. Dietmar Hopp...
Read More
BioCentury | Mar 16, 2020
Management Tracks

CureVac CEO Hoerr takes leave of absence; German biotech rejects reports of U.S. approach for COVID-19 vaccine

...CureVac’s largest shareholder, dievini Hopp BioTech holding GmbH & Co. KG, the investment vehicle of Dietmar Hopp...
Read More
BioCentury | Jan 5, 2018
Finance

BioNTech bonanza

...2015, fellow German mRNA play CureVac AG, which had been solely financed by German billionaire Dietmar Hopp...
Read More
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...innovative mRNA technology that has put four programs into the clinic; long-term investors such as Dietmar Hopp...
Read More
BioCentury | Nov 18, 2016
Finance

Diversifying CureVac

...Gates Foundation . Before 2015, CureVac had been solely financed by billionaire entrepreneur and investor Dietmar Hopp...
Read More
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...vaccine, which it hopes will attract a partner for Phase III testing. SAP AG co-founder Dietmar Hopp...
Read More
BioCentury | May 17, 2010
Finance

Hopped Up

Dietmar Hopp is retaining his position as one of Germany's most active financial supporters of European biotech. Last week, vaccine company CureVac GmbH announced that dievini Hopp BioTech holding GmbH & Co. KG., its major...
Read More
BioCentury | Jun 8, 2009
Finance

Managing Austerity

...to a more conservative approach to spending and the willingness of business angels such as Dietmar Hopp...
Read More
Items per page:
1 - 10 of 31
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...spots, with the billionaire family offices of Dietmar Hopp...
Read More
BioCentury | Aug 15, 2020
Finance

Big post-IPO gain for CureVac could presage volatile aftermarket

...then diversified its investor base as it prepared to go public. Billionaire entrepreneur and investor Dietmar Hopp...
Read More
BioCentury | Aug 11, 2020
Finance

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

...proposed range of $14-$16, it would raise $200 million and be valued at $2.6 billion. Dietmar Hopp...
Read More
BioCentury | Mar 16, 2020
Management Tracks

CureVac CEO Hoerr takes leave of absence; German biotech rejects reports of U.S. approach for COVID-19 vaccine

...CureVac’s largest shareholder, dievini Hopp BioTech holding GmbH & Co. KG, the investment vehicle of Dietmar Hopp...
Read More
BioCentury | Jan 5, 2018
Finance

BioNTech bonanza

...2015, fellow German mRNA play CureVac AG, which had been solely financed by German billionaire Dietmar Hopp...
Read More
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...innovative mRNA technology that has put four programs into the clinic; long-term investors such as Dietmar Hopp...
Read More
BioCentury | Nov 18, 2016
Finance

Diversifying CureVac

...Gates Foundation . Before 2015, CureVac had been solely financed by billionaire entrepreneur and investor Dietmar Hopp...
Read More
BioCentury | Sep 24, 2012
Finance

Hopp stays the course

...vaccine, which it hopes will attract a partner for Phase III testing. SAP AG co-founder Dietmar Hopp...
Read More
BioCentury | May 17, 2010
Finance

Hopped Up

Dietmar Hopp is retaining his position as one of Germany's most active financial supporters of European biotech. Last week, vaccine company CureVac GmbH announced that dievini Hopp BioTech holding GmbH & Co. KG., its major...
Read More
BioCentury | Jun 8, 2009
Finance

Managing Austerity

...to a more conservative approach to spending and the willingness of business angels such as Dietmar Hopp...
Read More
Items per page:
1 - 10 of 31